Introducing Valuation Models! 
Key Takeaways:
- Universal Health Services stock could reasonably reach $234/share by the end of 2027, based on our valuation assumptions.
- That implies a 27.5% total return from today’s price of $183/share, with an annualized return of 10.4% over the next 2.5 years.
- UHS operates as one of the largest hospital companies in the United States with leading positions in both acute care and behavioral health services.
Universal Health Services (UHS) is a healthcare services company that owns and operates acute care hospitals, behavioral health centers, and ambulatory surgery centers across the United States and the United Kingdom.
UHS benefits from normalized post-COVID operating conditions, well-controlled expenses, and strong demand for behavioral health services, while navigating regulatory uncertainties around Medicaid supplemental payment programs.
With over 400 facilities generating approximately $15 billion in annual revenue, UHS remains positioned as a diversified leader in healthcare services, offering multiple paths to sustainable growth.
Here’s why UHS stock could return 10% annually through 2027 and potentially continue solid performance through 2030.
Try TIKR’s Valuation Model today for FREE (It’s the easiest way to find undervalued stocks) >>>
What the Model Says for UHS Stock
We analyzed UHS’s potential using valuation assumptions based on its post-pandemic operational recovery and normalized growth trajectory.
Based on assumptions of 6.3% annual revenue growth, 10.8% operating margins, and stable valuation multiples, the model estimates UHS stock could rise from $183/share to $234/share.
That represents a 27.5% total return and a 10.4% annualized return over the next 2.5 years.
Value UHS with TIKR’s Valuation Model today for FREE (Find undervalued stocks fast) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for UHS stock:
1. Revenue Growth: 6.3%
UHS delivered solid Q1 results, with 5.0% growth in acute care same-facility revenue and 5.5% growth in behavioral health revenue.
Management guidance targets mid-single-digit revenue growth split between volume and pricing. We used a 6.3% forecast reflecting normalized post-COVID growth patterns and capacity expansion.
2. Operating Margins: 10.8%
UHS achieved strong expense controls, with operating expenses growing only 2.6% year-over-year, while revenues increased by 5%.
We project modest margin expansion as the healthcare giant benefits from operational leverage and controlled labor costs in a normalized environment.
3. Exit P/E Multiple: 9.2x
UHS stock currently trades at a forward P/E of 9.2x, which is lower than its historical averages.
We maintain current valuation levels given the company’s defensive characteristics and steady cash generation.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
TIKR’s valuation tool allows investors to test a wide range of outcomes based on how UNH stock performs through 2030 under different scenarios (these are estimates, not guaranteed returns):
- Low Case: Policy headwinds and competitive pressure → 2% annual returns.
- Mid Case: Steady execution and normalized growth trajectory → 7% annual returns.
- High Case: Operational leverage and market expansion → 12% annual returns.
Even in the conservative case, UHS offers modest positive returns, while the upside scenario could deliver attractive gains if multiple factors align favorably.
See analysts’ growth forecasts and price targets for any stock (It’s free!) >>>
TIKR Takeaway
Universal Health Services represents a solid defensive healthcare play with normalized growth prospects and operational leverage opportunities.
UHS stock provides steady exposure to essential healthcare services, backed by proven management execution and diversified revenue streams.
UHS stock is best suited for investors seeking exposure to healthcare services, companies with defensive characteristics and steady cash flows, and businesses positioned to benefit from demographic trends and capacity expansion.
The combination of post-COVID operational normalization, expense discipline, and capacity growth makes UHS an attractive consideration for healthcare-focused portfolios seeking stable, dividend-paying investments with modest growth potential.
Is UHS stock worth buying today? Use TIKR’s Valuation Model and analyst forecasts to see if it looks undervalued.
Value any stock with TIKR’s Valuation Model (It’s free!) >>>
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
